Shoreline Biosciences Acquires Editas’ iNK Cell Franchise, Related Gene Editing Technologies
Editas Medicine Inc (NASDAQ:EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies…